Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07822880) titled 'A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Thyroid Neoplasms
Carcinoma, Non-Small-Cell Lung
Intervention:
Drug: Selpercatinib
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: November 2026
Target Sample Size: 30
Countries of Recruitment:
India
To know more, visit https://clinical...